Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, double-blind trial of telbivudine versus lamivudine in adults with decompensated chronic hepatitis B and evidence of cirrhosis.

Next Previous
X
Search
Trial Profile

Randomized, double-blind trial of telbivudine versus lamivudine in adults with decompensated chronic hepatitis B and evidence of cirrhosis.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telbivudine (Primary) ; Lamivudine
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Idenix Pharmaceuticals; Novartis Pharmaceuticals

    • Most Recent Events

    • 15 Apr 2010 Two-year results were reported in an oral session at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) held in Vienna, Austria, on 14th-18th Apr 2010.
    • 30 Mar 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 30 Mar 2010 Planned number of patients (232) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top